In re Allergan, Inc. Proxy Violation Securities Litigation

Court: Central District of California
Case Number: 14-cv-2004
Judge: Hon. David O. Carter
Class Period: 02/25/2014 - 04/21/2014
Case Contacts: Mark Lebovitch, Jeremy P. Robinson, Michael D. Blatchley, Richard D. Gluck, Edward G. Timlin

This case involves allegations of insider trading and is brought on behalf of a class of investors who sold the common stock of Allergan, Inc. (“Allergan”) during the period from February 25, 2014 through April 21, 2014.   

Class Representatives Have Reached a Proposed Settlement for $250 Million

The Court-appointed representatives for the Class, State Teachers Retirement System of Ohio, Iowa Public Employees Retirement System, and Patrick T. Johnson, on behalf of themselves and the other members of the Class, have reached a proposed settlement with Defendants for $250,000,000 in cash that, if approved, will resolve all claims in the Action.

If you are a member of the Class and you did not previously request exclusion from the Class in connection with the Class Notice previously mailed in 2017, your rights will be affected by the Settlement and you may be eligible for a payment if the Settlement is approved.  The Class consists of:

all persons who sold Allergan common stock during the period February 25, 2014 through April 21, 2014, inclusive, and were damaged thereby

For the full definition of the Class, including persons and entities excluded from the Class, please read the Settlement Notice.

Please read the Settlement Notice to fully understand your rights and options in connection with Settlement.  Copies of the Settlement Notice and Claim Form can be found on the Case Documents page.  You may also visit the Settlement website,, for more information about the Settlement.

If you are a member of the Class, in order to be potentially eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked no later than August 7, 2018

Payments to eligible claimants will be made only if the Court approves the Settlement and a plan of allocation, and only after any appeals are resolved, and after the completion of all claims processing.  Please be patient, as this process will take some time to complete.


August 7, 2018

Claim Filing Deadline.  Claim Forms must be postmarked no later than August 7, 2018 to be eligible for a payment from the Settlement.

May 9, 2018

Objection Deadline.  Any objections to the proposed Settlement, the proposed Plan of Allocation, and/or the request for attorneys’ fees and litigation expenses, must be filed no later than May 9, 2018, in accordance with the instructions in the Settlement Notice.

June 12, 2018
at 4:00 p.m.

Settlement Hearing.  The Settlement Hearing will be held on June 12, 2018 at 4:00 p.m., before the Honorable David O. Carter at the United States District Court for the Central District of California, Ronald Reagan Federal Building, United States Courthouse, 411 West Fourth Street, Santa Ana, CA 92701, 9th Floor, Courtroom 9D, to determine, among other things, whether the proposed Settlement is fair, reasonable and adequate and should be approved; whether the proposed Plan of Allocation is fair and reasonable and should be approved; and whether Lead Counsel’s motion for an award of attorneys’ fees and litigation expenses should be approved.

Please note that the previously scheduled Settlement Hearing (as set forth in the Settlement Notice) has been rescheduled by the court to June 12, 2018 at 4:00 p.m.)


The Action alleges that, during the Class Period from February 25, 2014 through April 21, 2014, inclusive, hedge fund manager Bill Ackman, his fund Pershing Square Capital Management and related entities (the “Pershing Defendants”) acquired a 9.7% stake in Allergan while in possession of material nonpublic information relating to a contemplated takeover attempt for Allergan by Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, and J. Michael Pearson (collectively, the “Valeant Defendants”).

On April 21 and 22, 2014, the Valeant Defendants announced their takeover bid and the Pershing Defendants disclosed their stake.  Allergan’s stock price increased about 15% in the immediate aftermath of that announcement.  The Pershing Defendants’ profits from their Class Period transactions grew to well over $2 billion after a third-party, Actavis plc, agreed to acquire Allergan for cash and stock valued at approximately $219 per Allergan share. Of this amount, the Pershing Defendants paid approximately $400 million to the Valeant Defendants pursuant to a February 2014 agreement that the Pershing Defendants would share their gains with the Valeant Defendants in the event that a competing offer for Allergan was successful, and retained the rest.

The federal securities laws expressly prohibit anyone from trading on nonpublic information about an upcoming tender offer.  The purpose of the securities laws that govern tender offers such as this one is to create a level and fair playing field so that insiders with knowledge about an upcoming tender offer cannot profit from trading with unsuspecting investors who are not privy to such information.  The action asserts claims under Section 14(e) and Rule 14e-3 of the Securities Exchange Act on behalf of Allergan investors that sold their shares during February 25, 2014 and April 21, 2014 (the “Class Period”) – the period during which Ackman was secretly acquiring his stake in Allergan. 

On May 5, 2015, the Court appointed BLB&G client the State Teachers Retirement System of Ohio as Co-Lead Plaintiff, together with its Co-Lead Plaintiff the Iowa Public Employees Retirement System.  On August 7, 2015, Defendants moved to dismiss the claims against them.  Lead Plaintiffs opposed the motion and, on November 9, 2015, the Court denied Defendants’ motion in its entirety.  

On March 15, 2017 the Court entered an Order certifying the Action to proceed as a class action on behalf of the Class defined above, appointing State Teachers Retirement System of Ohio, Iowa Public Employees Retirement System, and Patrick T. Johnson as Class Representatives, and appointing BLB&G and co-counsel Kessler Topaz Meltzer & Check, LLP as Class Counsel.  Notice of the pendency of the class action was mailed to potential Class Members beginning in July 2017.  If Class Members wished to exclude themselves from the Class, they were required to have submitted a request for exclusion by September 11, 2017.

Between January 2016 and June 2017, the Parties completed extensive fact and expert discovery in the Action, including conducting over 50 depositions and producing more than 1.5 million pages of documents in document discovery.  Defendants’ motions for summary judgment, both Plaintiffs’ and Defendants’ motions to exclude the other side’s expert testimony, and Plaintiffs’ motion to bifurcate the trial were full briefed and pending before the Court at the time the Parties reached their agreement to Settlement.  In addition, the Parties had engaged in substantial preparations for trial before the Settlement was reached. 

On February 26, 2018, the Parties entered into the Stipulation and Agreement of Settlement.  If approved by the Court, the Settlement will settle and release all claims asserted in the Action in return for a $250 million cash payment.

Other Cases of Interest

  • SMART Technologies, Inc.
    Southern District of New York Hannah Ross, Jeremy P. Robinson
  • Lehman Brothers Holdings
    Southern District of New York Max W. Berger, David R. Stickney, Benjamin Galdston, Brett M. Middleton, Richard D. Gluck,
  • Wilmington Trust
    District of Delaware Hannah Ross, Lauren McMillen Ormsbee, Richard D. Gluck, Katherine M. Sinderson, Julia Tebor, Jesse L. Jensen
  • Twenty-First Century Fox, Inc.
    Delaware Chancery Court Max W. Berger, Mark Lebovitch, David Wales, Rebecca E. Boon
  • Sanchez Energy
    Delaware Court of Chancery David Wales, Mark Lebovitch, Christopher J. Orrico, Alla Zayenchik
  • Citigroup, Inc.
    Southern District of New York John C. Browne, David Wales, John Rizio-Hamilton, Benjamin Galdston, Jeremy P. Robinson
  • Allergan, Inc. (Proxy Violation)
    Central District of California Mark Lebovitch, Jeremy P. Robinson, Michael D. Blatchley, Richard D. Gluck, Edward G. Timlin
  • Morgan Stanley & Co., Inc.
    District of Massachusetts Gerald H. Silk, David R. Stickney, David Wales, Timothy A. DeLange, Jonathan D. Uslaner, Lauren McMillen Ormsbee, Jai K. Chandrasekhar, Rebecca E. Boon, Richard D. Gluck
  • Vale SA
    Southern District of New York John C. Browne, Timothy A. DeLange, Richard D. Gluck, Rebecca E. Boon, Jenny E. Barbosa, Robert Trisotto